Kipco Electronics & Aerospace Co. Ltd cancelled the acquisition of From2 Information & Communication Co., Ltd from HLB Life Science Co.,Ltd..
June 13, 2018
Share
Kipco Electronics & Aerospace Co. Ltd agreed to acquire From2 Information & Communication Co., Ltd from HLB Life Science Co.,Ltd. (KOSDAQ:A067630) for KRW 3.5 billion on June 14, 2017. Under the terms, HLB Life Science Co Ltd will sell 0.22 million shares. After acquisition, HLB Life Science Co Ltd will not hold any stake in From2 Information & communications Co., Ltd. The payment will be made on closing. The transaction is expected to close on September 13, 2017. As on September 13, 2017, expected closing date extended to December 31, 2017. As of October 13, 2017, the transaction's expected closing date was modified to October 16, 2017.
Kipco Electronics & Aerospace Co. Ltd cancelled the acquisition of From2 Information & Communication Co., Ltd from HLB Life Science Co.,Ltd. (KOSDAQ:A067630) on June 14, 2018.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
HLB LIFE SCIENCE CO., LTD. 
